These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 12850842

  • 1. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM.
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [Abstract] [Full Text] [Related]

  • 2. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
    Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D.
    Thromb Res; 2002 Sep 15; 107(6):303-17. PubMed ID: 12565717
    [Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM.
    J Clin Pharmacol; 2002 Jul 15; 42(7):738-53. PubMed ID: 12092741
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL.
    Am J Cardiovasc Drugs; 2003 Jul 15; 3(2):101-12. PubMed ID: 14727937
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
    Caron A, Théorêt JF, Mousa SA, Merhi Y.
    J Cardiovasc Pharmacol; 2002 Aug 15; 40(2):296-306. PubMed ID: 12131559
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.
    J Pharmacol Exp Ther; 2002 Dec 15; 303(3):1114-20. PubMed ID: 12438534
    [Abstract] [Full Text] [Related]

  • 11. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.
    Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148
    [Abstract] [Full Text] [Related]

  • 12. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL, Malinin AI, O'connor CM, Gurbel PA, Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy.
    Am Heart J; 2003 Jul 01; 146(1):91-8. PubMed ID: 12851613
    [Abstract] [Full Text] [Related]

  • 13. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Jul 01; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD.
    Circulation; 2001 Sep 18; 104(12):1374-9. PubMed ID: 11560852
    [Abstract] [Full Text] [Related]

  • 20. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 18; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.